linjc16/ctgov huggingface dataset:
Hip Arthroscopy Improves Muscle Volumes in Patients With Femoroacetabular Impingement Syndrome

Study Overview
=================
Brief Summary
-----------------
To explore the changes of the muscles around the hip joint after hip arthroscopy for patients with femoral acetabular impingement syndrome.

Detailed Description
-----------------
Retrospectively investigate the influence of hip arthroscopy on the muscle volume around the hip joint, and to provide important information for clinicians to make diagnosis and treatment plan of hip joint disease.

Official Title
-----------------
The Influence of Hip Arthroscopy on Postoperative Muscle Volumes in Patients With Femoroacetabular Impingement Syndrome

Conditions
-----------------
Femoroacetabular Impingement Syndrome

Intervention / Treatment
-----------------
* Other: Muscle volumes were measured on pre- and postoperative MRI scans.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: (1) Age 18-50 years old; (2) Diagnosed femoroacetabular impingement syndrome; (3) Conservative treatment ineffective; (4) complete preoperative and postoperative MRI images; - Exclusion Criteria: (1) bilateral; (2) revision; (3) osteoarthritis; (4) acetabular dysplasia; (5) history of hip and knee joint disease or surgery; (6) femoral head necrosis; (7) sacroiliac joint disease. -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>Patients with femoroacetabular impingement syndrome and underwent hip arthroscopy。 | Other: Muscle volumes were measured on pre- and postoperative MRI scans.<br>* Muscle volumes were measured on pre- and postoperative MRI scans.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscle volumes | Difference between pre- and postoperative muscle volumes | 1 year after hip arthroscopy |
Efficacy and Safety of a Sore Throat Lozenge Containing Lidocaine and Cetylpyridinium Chloride in Patients With Sore Throat Due to a Common Cold.

Study Overview
=================
Brief Summary
-----------------
This study will compare the efficacy and safety of a single dose of a lidocaine 8 mg + cetylpyridimium chloride (CPC) 2 mg lozenge with a single dose of a lidocaine 1 mg + CPC 2 mg lozenge in the treatment of sore throat due to a common cold.

Official Title
-----------------
A Randomized, Double-blind, Parallel Group, Single-dose Study of the Efficacy of Lidocaine 8 mg + Cetylpyridinium Chloride (CPC) 2 mg Fixed Combination Lozenges on Sore Throat Pain Intensity Compared to Lozenges Containing Lidocaine 1 mg and CPC 2 mg in Subjects With Sore Throat Due to Upper Respiratory Tract Infection.

Conditions
-----------------
Sore Throat Due to a Common Cold

Intervention / Treatment
-----------------
* Drug: Lidocaine 8mg + CPC 2mg
* Drug: Lidocaine 1mg + CPC 2mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with sore throat due to an upper respiratory tract infection, with recent onset (within 48 hours) Sore throat of at least moderate pain intensity Exclusion Criteria: - History of hypersensitivity to any of the study drugs and listed excipients or to drugs of similar chemical classes Evidence of mouth breathing or severe coughing Evidence of overt oropharyngeal bacterial or fungal infection or evidence of lower respirator tract infection Severe renal, liver or cardiac impairment Severe lung disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lidocaine 8mg +CPC 2mg<br>one single dose | Drug: Lidocaine 8mg + CPC 2mg<br>* one single dose<br>|
| Active Comparator: Lidocaine 1mg + CPC 2mg<br>one single dose | Drug: Lidocaine 1mg + CPC 2mg<br>* one single dose<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline Sore Throat Pain Intensity | 100 milimeter (mm) visual acuity score (left=no pain=0mm, right=worst possible pain=100mm) | Baseline and 2 hours post-dose | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline Sore Throat Pain Intensity up to 240 mn Post-dose | 100 milimeter (mm) visual acuity score (left=no pain=0mm, right=worst possible pain=100mm). It measures the highest pain level felt by the patient. | Baseline and 240 mn post-dose | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sore throat, upper respiratory tract infection, lozenge with lidocaine and cetylpyridinium chloride.
Bleb Vascularity Change After Subconjunctival Injection Bevacizumab

Study Overview
=================
Brief Summary
-----------------
The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.

Official Title
-----------------
Bleb Vascularity Change After Subconjunctival Injection of Bevacizumab

Conditions
-----------------
Bleb Vascularity, Conjunctival Scarring

Intervention / Treatment
-----------------
* Drug: bevacizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Glaucoma patients after trabeculectomy whose bleb is hyperaemia Exclusion Criteria: Affected eye has normal IOP Not allergic with Avastin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: bevacizumab|0.05ml, 1.25mg|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bleb vascular change |  | one day, one week, one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bleb, vascular change, bevacizumab, trabeculectomy, Bleb vascularity associated with increased scarring activity, Conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery, the recombinant human anti-VEGF antibody could inhibit angiogenesis of conjunctiva.
Antipsychotic Medicine and Metabolic Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine whether antipsychotic treatment is influence psychiatric patients due to endocrine and metabolic status and a quality of life. The investigators expect, that 30-50% of patients will show pharmacon - gene induced weight gain (> 7% of initial bodyweight) while the rest of patients will maintain unaltered bodyweight.

Detailed Description
-----------------
The primary aim of this study is to investigate status of neuro-and enteroendocrine axes with focus on beta - cell function in relation to insulin resistance, lipid profile abnormalities and inflammations adipokins in patients during treatment with antipsychotics (AP) in relation to weight gain. The second aim is to evaluate the connection between weight gain and patients´ own perception of their quality of life and health.

Official Title
-----------------
Changes in Enteroendocrine and Neuroendocrine Axes in Patients With Weight Gain After Treatment With Antipsychotics

Conditions
-----------------
Metabolic Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: gender : male age: 18-45 treatment with minimum one Antipsychotic drug (AP) ethnicity: caucasians consent given to take part in the project Exclusion Criteria: One criteria is sufficient to exclude patients from the study: compliance problems unable to read, write and talk Danish patients with major lung-,heart-, lever- and kidney problems patients with diagnose and treatment for Diabetes 1 and 2 patients taking cholesterol-reducing, weight-reducing and antihypertensive medication patients with abuse of alcohol or drugs patients who are under duress § patients who have been mentally ill for more than 15 years patients with diagnosis/treatment for NIDDM/IDDM

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Food challenge test<br>Patients 51 patients included | |
| C<br>Controls 93 healthy controls are included | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
metabolic syndrome, weight gain, antipsychotic drugs, Metabolic syndrome and treatment with antipsychotic drugs
Traditional Electrosurgery System Versus Low Thermal Tissue Dissection System for Total Mastectomy

Study Overview
=================
Brief Summary
-----------------
Breast cancer is one of the most common cancer among women nowadays. There are lots of modality of treatment and one of them is Mastectomy. We found out that seroma is one of the disturbing postoperative complications after mastectomy. In our study we want to compare the outcome between using the conventional electrocautery and the low thermal tissue dissection. We expected that the serum production should be lower in cases using low thermal system electrosurgery system.

Official Title
-----------------
Comparison of Traditional Electrosurgery System Versus Low Thermal Tissue Dissection System for Total Mastectomy: A Prospective Randomized Controlled Trial

Conditions
-----------------
Seroma

Intervention / Treatment
-----------------
* Device: Low thermal electrosurgery system
* Device: Conventional Electrocautery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female aged >18 years old Patients that fulfill the indication of mastectomy Medium-sized breast volume (Breast weight < 1500 grams) Exclusion Criteria: Patients who cannot complete the informed consent Patients with ASA CLASS > 3

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Device Feasibility
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Conventional electrocautery<br> | Device: Conventional Electrocautery<br>* Conventional Electrocautery<br>|
| Experimental: Low thermal electrosurgery system<br> | Device: Low thermal electrosurgery system<br>* PEAK Plasmablade<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Drainage volume after surgery | Drainage volume detected after surgery which is measured in drainage container and measured by syringe gauge aspiration | Up to 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post operative Pain | Post-operative Pain measured using 0-10 Numeric pain scale | Up to 24 weeks | 
| Patient's Hospital costs | Expenses that the patient has to pay while staying in the hospital | up to 1 week | 
| Wound infection | Wound infection after surgery | Up to 24 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mastectomy, Seroma
PReventive Efficacy and Safety of rEbamipide on Nsaid Induced Mucosal Toxicity

Study Overview
=================
Brief Summary
-----------------
To prove that the efficacy and safety of Mucosta® (Rebamipide) is non-inferior to those of Cytotec® (Misoprostol), in terms of prevention of NSAID-induced gastric ulcer.

Official Title
-----------------
A Phase III, Randomized, Double-dummy, Double Blind, Misoprostol-comparative Clinical Trial to Evaluate the Efficacy and Safety of Mucosta® Tablet in the Prevention of NSAID-induced Gastrointestinal Complications

Conditions
-----------------
Rheumatoid Arthritis, Osteoarthritis, Ankylosing Spondylitis

Intervention / Treatment
-----------------
* Drug: Rebamipide
* Drug: Misoprostol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed written informed consent after being informed of the clinical trial Males or females 19 years of age Intake of any brand of NSAIDs in more than half of daily dose for at least the previous 4 weeks. Exclusion Criteria: Necessary to proceed in concomitant treatment with epileptic medications, anti-chollinergics, prokinetics, sucralfate Presence or history of allergic drug reaction to the following medications; rebamipide, Misoprostol, NSAIDs designated to the protocol

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: Rebamipide<br>* Rebamipide 100㎎, 12 weeks<br>* Other names: Mucosta;|
| Active Comparator: 2<br> | Drug: Misoprostol<br>* Misoprostol 200㎍ 12 weeks<br>* Other names: Cytotec®;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence rate of gastric ulcer on gastroendoscopy result at 12-week |  | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of Therapeutic failure |  | 12 weeks | 
| Severity of gastrointestinal symptoms |  | 12 weeks | 
| Antacid consumption |  | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Patients with rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis or any other arthritis-like disease requiring continuous NSAIDs therapy
Quality of Life and Sexuality in Women With Gynaecological Cancer

Study Overview
=================
Brief Summary
-----------------
Patients with premalignant (CIN3) and malignant cervical cancer will asked to complete questionnaires regarding intimacy (ENRICH) and life adaptation (PAIS) before treatment (surgery or radiotherapy) and after completion of treatment in order to estimate the influence of disease and treatment on quality of life indices.

Detailed Description
-----------------
no additional information. see above

Official Title
-----------------
Quality of Life and Sexuality in Women With Gynaecological Cancer

Conditions
-----------------
Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women with Gynaecological cancer intended to undergo chemotherapy or surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group A group B<br>A:Patients for surgical intervention B:Patients for radiotherapy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life | longitudinal describtion of quality of life during treatment | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gynaecological Cancer, Quality of Life, Sexuality
Maintenance Therapy Using Lenalidomide in Myeloma

Study Overview
=================
Brief Summary
-----------------
Maintenance treatment of myeloma.

Official Title
-----------------
Relevance of Maintenance Therapy Using Lenalidomide (Revimid®) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).

Conditions
-----------------
Myeloma

Intervention / Treatment
-----------------
* Drug: lenalidomide
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No signs of progression after transplant Effective contraception if necessary (oral contraception for females and barrier methods of contraception for sexually active males) No active severe infection Satisfactory restoration of the haematological parameters defined by: PN >1,000/mm3 and Platelets > 75,000/mm3 Bilirubin < 35 umol/l and GOT/GPT/PAL<3N Creatinine < 160 umol/l.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: placebo group<br>Administration of oral placebo | Drug: placebo<br>* oral placebo<br>|
| Experimental: lenalidomide group<br>Administration of lenalidomide | Drug: lenalidomide<br>* oral drug<br>* Other names: REVLIMID;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine the efficacy of Revlimid® at prolonging the duration of the post-transplant response. |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess the impact of Revlimid® on the post-transplant complete response rate |  | 2 years | 
| Compare survival without events and overall survival of patients in the lenalidomide arm with the control |  | 2 years | 
| Evaluate the long-term tolerance of Revlimid® in post-transplant maintenance therapy. |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Myeloma, Revlimid, Maintenance therapy, Autologous Stem Cell Transplantation
Korean Hereditary Breast Cancer Study

Study Overview
=================
Brief Summary
-----------------
To evaluate the prevalence of BRCA1/2 mutation of breast cancer patients with family history of breast/ovarian cancer. To evaluate the prevalence of BRCA1/2 mutation of breast cancer patients without family history, but high risk of hereditary cancer. To evaluate the prevalence of BRCA1/2 mutation of family member of BRCA1/2 mutation. To evaluate the prevalence of ovarian cancer of population of above 3 groups.

Detailed Description
-----------------
To find founder mutation in Korean To correlation prevalence with risk evaluation To find risk factors concerning life style

Official Title
-----------------
Korean Hereditary Breast Cancer Study

Conditions
-----------------
Breast Cancer, Ovarian Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 19 years old Agree to this study Breast cancer patient with family history of breast/ovarian cancer (1 subgroup) Breast cancer patient; young age (<40), bilateral, male, combined ovarian (2 subgroup) Family members with 1, 2 subgroups (3 subgroup) Exclusion Criteria: Under 20 years old Unable to decide for oneself

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Find out the prevalence of BRCA1/2 mutation of high risk breast cancer patients |  | 6 years |